Inflammatory myopathy is characterized by proximal muscle weakness which is highly suspected through an autoimmune pathogenesis. Extramuscular manifestations including fever, arthralgia, and pulmonary complications are common. 1 Diagnosis of both polymyositis (PM) and dermatomyositis (DM) relies on characteristic clinical manifestations, increased serum muscle enzymes, and a standard electromyography (EMG). Periorbital edema is often accompanied by a heliotrope rash. 1 However, subcutaneous edema in limbs is extremely rare. A literature search uncovered 33 cases of limb edema associated with inflammatory myopathy, of whom seven were localized edema, while the remaining were considered generalized edema. All seven patients with localized edema were diagnosed with DM. In this article, we report on a case of PM with localized subcutaneous edema and hepatocellular carcinoma (HCC). To the best of our knowledge, this is the first case of localized edema to be associated with PM.
CASE REPORT
A 66-year-old male patient was admitted to our medical center having experienced progressive proximal symmetric muscle weakness and myalgia for six weeks, along with left arm swelling and pain for three weeks. He was a hepatitis B virus (HBV) carrier without any regular follow-ups. Otherwise, he displayed no human immunodeficiency virus infection, alcohol abuse or recent illegal drug administration. Upon arrival, his vital signs were stable without showing any cardiopulmonary distress. A physical examination demonstrated prominent non-pitting edema at his left arm and forearm without any signs of redness, warmth, or tenderness. No palpable neck or axillary lymphadenopathy was found. A neurological examination resulted in a muscle power score of four in the thighs and arms. The patient's sensation was intact and the deep tendon reflexes were normal. There was no typical rash resulting from DM or signs of Raynaud phenomenon. Laboratory values included C-reactive protein at 1.1 mg/dL, creatine kinase (CK) level of 4,325 U/L, lactate dehydrogenase of 446 U/L, and aspartate aminotransferase of 231 g/dL. Thyroid function, renal test results, and electrolyte levels were within normal limits. The antinuclear antibody titer was 1:80, displaying a fine speckled pattern (positive ≥1:160). The anti-Jo-1 antibody was negative. The electromyographic findings showed abnormal electrical irritability and short duration consistent with inflammatory myopathy. A nailfold capillary microscope revealed avascular zones and enlarged loops which supported the diagnosis of PM. This retrospective case study was approved by our Institution Review Board (protocol number: CE17124B).
Multi-detector row computed tomography showed prominent subcutaneous edema at the left upper arm and forearm ( Figure 1 ). No venous thrombosis or stenosis was noted The patient's left upper limb edema gradually improved through the use of intravenous dexamethasone at a dose of 5 mg twice daily (equivalent to 0.7 mg/kg/day of prednisolone). This was followed by an oral dose of methylprednisolone at 16 mg per day (equivalent to 0.3 mg/kg/day of prednisolone). The patient's muscle weakness also improved, and he experienced a continuous decrease in his blood CK level (866 U/L on day 13). Hydroxychloroquine 400 mg per day was administered for immunomodulation. The patient was discharged on the 13 th day of his hospital stay. During the two-month outpatient follow-up period, no recurrence of left upper limb edema was noted, although mild fluctuations in muscle power and blood CK level were noted. He died on HCC three months after the date of diagnosis.
DISCUSSION
This case involved PM with HCC, along with localized subcutaneous non-pitting edema in the left arm. The clinical, laboratory, and EMG evaluations were all compatible with PM. We researched the causes of both pitting and nonpitting edema (e.g., hypothyroidism, renal failure, congestive heart failure, liver cirrhosis, and deep vein thrombosis) but all were unremarkable. The patient's localized non-pitting edema was recovered through treatment using systemic corticosteroid and hydroxychloroquine.
Bohan and Peter criteria 2 have been the most widely-used classification criteria for inflammatory myopathies over the past decades; however, several limitations have created difficulties in their interpretation. Tanimoto et al. 3 proposed a new classification criteria which included eight items: (1) proximal muscle weakness, (2) elevated serum CK or aldolase levels, (3) muscle pain on grasping or spontaneous pain, (4) myogenic changes on EMG, (5) positive anti-Jo-1 antibodies, (6) nondestructive arthritis or arthralgias, (7) systemic inflammatory signs, and (8) pathological findings compatible with inflammatory myositis. When a patient meets at least four of these items, other than skin lesion items, he or she shall be classified as having PM. Our patient met the items of 1, 2, 3, 4, and 7, therefore PM was diagnosed. A muscle biopsy is a simple procedure; however, it may lead to some complications such as bruising, prolonged bleeding, or wound infection. Since prominent subcutaneous edema may result in poor wound healing, 4 a muscle biopsy was not performed on our patient.
Subcutaneous edema is a very rare clinical presentation of inflammatory myopathy. To our knowledge, our case is the first to document localized edema associated with PM. We performed a review of the literature using the MEDLINE [PubMed], and included case reports, series and reviews. The search terms used included "dermatomyositis", "polymyositis", and "edema". We located 33 relevant articles published between 1982 and 2016. Information regarding age, distribution of edema, malignancy, treatment modality, along with responses extracted from the above articles and our case, was outlined in Table 1 .
The mean age was 54.8 years (range 23-93). Nineteen patients (55.9%) were female. Eight patients (23.5%) experienced localized subcutaneous edema while 26 patients (76.5%) had generalized subcutaneous edema. Six patients (17.6%) were associated with PM, and 28 patients (79.4%) were associated with DM. The subcutaneous edema recovered spontaneously in two cases, and through corticosteroid treatment in seven cases. 2, 4, 5, 11, 13, 20, 23 Immunosuppressants for these patients included azathioprine, methotrexate, cyclophosphamide, or mycophenolate mofetil (n=9) and tacrolimus (n=2). Thirteen cases received intravenous immunoglobulin. 7, 10, [14] [15] [16] [17] [18] 21, 22 Our case received the medium dose of corticosteroid in adjunction with hydroxychloroquine, and the clinical response in resolving localized edema was good.
In general, the incidence of malignancy in DM was higher than that in PM. The association between malignancy and DM was established; however, it is less convincing in PM. A nationwide cohort study of the relationship between malignancy and inflammatory myopathy in Taiwan showed an incidence of 4.4% in PM and 9.4% in DM. 27 As for our review, the prevalence of malignancy in PM-and DM-associated subcutaneous edema was 50% (1/2) and 10% (2/20), respectively. The recognition of malignancy could be either through tissue pathology or imaging. Twelve cases were without mention of tumor survey, while four with a past malignancy without recurrence were excluded from the analysis. There is a considerable risk of malignancy in patients with both inflammatory myopathy and subcutaneous edema; therefore, a comprehensive tumor survey is recommended.
The pathophysiology of edema has been well documented, and includes Starling forces, change in capillary permeability, reduction of effective arterial volume, renal factors, and the renin-angiotensin-aldosterone system, along with natriuretic peptides. However, the mechanism of subcutaneous edema for inflammatory myositis remains unclear. Lymphatic blockage has been proposed as the cause of severe edema. 22 Another possible cause is widespread active vasculitis. 15 Most patients with cancer-associated dermatomyositis display antibodies to the nuclear matrix protein-2 (NXP-2). 28 Rogers et al. 29 demonstrated a novel relationship between the NXP-2 antibody and peripheral edema in adult DM patients. However, the cause of peripheral edema in DM patients remains unclear, and thus requires further investigation.
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